Nova Eye Medical Ltd · ASX:EYE
Nova Eye Medical — H1 FY25 Earnings Presentation
11 slides from Nova Eye Medical's earnings presentation, Feb 26, 2025
Slide 1: Nova Eye Medical Limited (ASX:EYE) Investor Presentation
Nova Eye Medical Limited (ASX:EYE) Investor Presentation Selling highly effective products that eye surgeons want into a market that is large and growing nova-eye.com | 1 February 2025
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Nova Eye Medical Limited (ASX: EYE). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any st
Slide 3: Highlights
Highlights • Balance sheet strengthened • Completed a successful capital raise(1) to strengthen its financial position and support ongoing growth. • Robust Global Performance Continues • Global sales rose 39% (in constant currency including 48% in the USA) during the year to 31 December 2024 compare
Slide 4: Robust Revenue Growth Being Achieved
Robust Revenue Growth Being Achieved Group sales 3 years to 31 December 2024 (1) 18,000,000 45% 16,000,000 40% 39% 14,000,000 35% 12,000,000 30% Growth on PCP 10,000,000 25% US$ 8,000,000 20% 6,000,000 15% 16% 4,000,000 10% 11% 2,000,000 5% - 0% 12 mths Dec 22 12 mths Dec 23 12 months Dec 24 • Incre
Slide 5: Revenue by Sales Territory
Revenue by Sales Territory Trailing Trailing 6 months to 6 months to Growth on Growth on US $000’s 12 months to 12 months to 31 31 Dec 23 31 Dec 24(1) PCP PCP 31 Dec 23 Dec 24(1) USA 5,050 6,477 28% 8,614 12,777 48% Germany 718 869 21% 1,355 1,720 27% China 315 710 125% 1,052 1,385 32% ROW 537 329 -
Slide 6: USA Sales Continue to Grow
USA Sales Continue to Grow • Five consecutive half-year periods of growth in USA following USA sales growth H1FY23 to H1FY25 introduction of iTrack Advance in April 2023 (H2 FY23). 7,000,000 • Growth rate in FY25 impacted by supply chain problems. 6,000,000 • Continued revenue growth demonstrates su
Slide 7: Nova Eye Glaucoma Surgical Device Sales Model
Nova Eye Glaucoma Surgical Device Sales Model Canaloplasty surgery has a well-established CPT1 code authorised by the USA CMS2 Eye surgeon selects Nova Eye delivers the The operating notes are submitted to Nova Eye product. product to the Facility and Medicare Administrative Contractor invoices the
Slide 8: Growth Metrics in Markets with Direct Sales Channels
Growth Metrics in Markets with Direct Sales Channels Annualised Field sales Annualised revenue per revenue per rep Team Growth Proposed Sales Team representatives at rep (weighted average) (weighted average) planned Totals 31 December 2024 six months to June 2024 12 months to December 2024 USA 11(1)
Slide 9: Operating Results for Glaucoma Segment
Operating Results for Glaucoma Segment % of % of % of US$000 H1 FY24 sales H2 FY24 sales H1 FY25 sales Revenue 6,673 8,565 8,468 COGS (1,996) (2,234) (2,878) Gross Margin 4,676 6,331 5,590 70% 74% 66% Less opex Sales, marketing and clinical (4,649) 70% (4,920) 57% (5,726) 68% Quality, regulatory and
Slide 10: Progressing to Breakeven on Group Cash Flow
Progressing to Breakeven on Group Cash Flow Group cash outflow from operations 3,000 Cash Outlow in A$000s per qtr 2,500 2,000 1,500 1,000 500 - Qtr ended Sept 23 Qtr ended Dec 23 Qtr ended Mar 24 Qtr ended Jun 24 Qtr ended Sep 24 Qtr ended Dec 24 (Q1FY24) (Q2FY24) (Q3FY24) (Q4FY24) (Q1FY25) (Q2FY25
Slide 11: Tom Spurling, Mark Flynn
Tom Spurling Mark Flynn Managing Director Investor Relations +61 8 8362 0193 +61 416 068 733 tspurling@nova-eye.com mflynn@nova-eye.com nova-eye.com | 11